Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: Clinical utility of the QuantiFERON-CMV assay for management of posttransplant CMV infection

Journal of Clinical Microbiology

Volumn 56, Issue 4, 2018, Pages

  Chiereghin, Angela ^a   Potena, Luciano ^a   Borgese, Laura ^a   Gibertoni, Dino ^b   Squarzoni, Diego ^a   Turello, Gabriele ^a   Petrisli, Evangelia ^a   Piccirilli, Giulia ^a   Gabrielli, Liliana ^a   Grigioni, Francesco ^a   Lazzarotto, Tiziana ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cell mediated immunity; CMV DNAemia; cytomegalovirus; Cytomegalovirus prevention strategies; Heart transplant

Indexed keywords

VALGANCICLOVIR; ANTIVIRUS AGENT; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNE RECONSTITUTION; IMMUNE RESPONSE; INCIDENCE; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; AGED; BLOOD; CLINICAL TRIAL; DEVICES; GENETICS; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; ISOLATION AND PURIFICATION; ITALY; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; VIREMIA; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; ITALY; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TRANSPLANT RECIPIENTS; VALGANCICLOVIR; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 85044776006     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01040-17     Document Type: Article

References (15)

1. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. 2013. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 56:817– 824. https://doi.org/10.1093/cid/cis993.
2. Durante-Mangoni E, Andini R, Pinto D, Iossa D, Molaro R, Agrusta F, Casillo R, Grimaldi M, Utili R. 2015. Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: a single centre, prospective cohort study. J Clin Virol 68:37–42. https://doi.org/10.1016/j.jcv.2015.04.017.
3. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A; Transplantation Society International CMV Consensus Group. 2013. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96: 333–360. https://doi.org/10.1097/TP.0b013e31829df29d.
4. Roman A, Manito N, Campistol JM, Cuervas-Mons V, Almenar L, Arias M, Casafont F, del Castillo D, Crespo-Leiro MG, Delgado JF, Herrero JI, Jara P, Morales JM, Navarro M, Oppenheimer F, Prieto M, Pulpón LA, Rimola A, Serón D, Ussetti P; ATOS working group. 2014. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev (Orlando) 28:84–91. https://doi.org/10.1016/j.trre.2014.01.001.
5. Weseslindtner L, Kerschner H, Steinacher D, Nachbagauer R, Kundi M, Jaksch P, Simon B, Hatos-Agyi L, Scheed A, Klepetko W, Puchhammer-Stöckl E. 2012. Prospective analysis of human cytomegalovirus DNAemia and specific CD8 T cell responses in lung transplant recipients. Am J Transplant 12:2172–2180. https://doi.org/10.1111/j.1600-6143.2012.04076.x.
6. Crough T, Khanna R. 2009. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 22:76–98. https://doi.org/10.1128/CMR.00034-08.
7. Calarota SA, Aberle JH, Puchhammer-Stöckl E, Baldanti F. 2015. Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications. J Clin Virol 70:109–119. https://doi.org/10.1016/j.jcv.2015.07.299.
8. Kumar D, Mian M, Singer L, Humar A. 16 June 2017. An interventional study using cell mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant https://doi.org/10.1111/ajt.14347.
9. Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, Bell S, Gailbraith A, McNeil K, Jones S, Khanna R. 2007. Ex vivo monitoring of human cytomegalovirus-specific CD8 T-cell responses using QuantiFERON®-CMV. Transpl Infect Dis 9:165–170. https://doi.org/10.1111/j.1399-3062.2006.00199.x.
10. Chiereghin A, Piccirilli G, Turello G, Squarzoni D, Pavia C, Gabrielli L, Landini MP, Lazzarotto T. 18 October 2016. Monitoring of cytomegalovirus (CMV) infection in solid organ transplant recipients: quantitation of CMV DNAemia by two Real-Time PCR assays. Microbiol Med 31:5963. https://doi.org/10.4081/mm.2016.5963.
11. Delgado JF, Manito N, Almenar L, Crespo-Leiro M, Roig E, Segovia J, Vázquez de Prada JA, Lage E, Palomo J, Campreciós M, Arizón JM, Rodríguez-Lambert JL, Blasco T, de la Fuente L, Pascual D, Rábago G. 2011. Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study. Transpl Infect Dis 13:136–144. https://doi.org/10.1111/j.1399-3062.2010.00573.x.
12. Mendez-Eirin E, Paniagua-Martín MJ, Marzoa-Rivas R, Barge-Caballero E, Grille-Cancela Z, Cañizares A, Naya-Leira C, Gargallo-Fernández P, Castro-Beiras A, Crespo-Leiro M. 2012. Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy. Transplant Proc 44:2660 –2662. https://doi.org/10.1016/j.transproceed.2012.09.035.
13. Potena L, Solidoro P, Patrucco F, Borgese L. 2016. Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update. Expert Opin Pharmacother 17:1611–1622. https://doi.org/10.1080/14656566.2016.1199684.
14. Fernández-Ruiz M, Kumar D, Humar A. 2014. Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunol 3:e12. https://doi.org/10.1038/cti.2014.3.
15. ® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One 8:e74744. https://doi.org/10.1371/journal.pone.0074744.